FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference
Marie‐Liesse Piketty, Séverine Brabant, Jean–Claude Souberbielle, Gérard Maruani, Christelle Audrain, Anya Rothenbühler, Dominique Prié, Agnès Linglart
Abstract
Article FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference was published on November 1, 2020 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 58, issue 11).
Topics & Concepts
Interference (communication)MedicineInternal medicineComputer scienceTelecommunicationsChannel (broadcasting)Parathyroid Disorders and TreatmentsFibroblast Growth Factor ResearchPituitary Gland Disorders and Treatments